Abstracts tagged "physical function"

Abstract Number: 0386 • ACR Convergence 2023
Functional Disability and Disease Activity Are Affected by Social Determinants of Health in Patients with Rheumatoid Arthritis
Mohammad Movahedi¹, Kangping Cui², George Tomilnson³, Angela Cesta³, xiuying Li³ and Claire Bombardier⁴, ¹Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada, ²Sunnybrook Hospital, Toronto, ON, Canada, ³University Health Network, Toronto, ON, Canada, ⁴University of Toronto, Toronto, ON, Canada
Background/Purpose: The relationship between social determinants of health (SDH) (e.g. income, education, and employment status) and disease outcomes in the RA population is not well…
Abstract Number: 2580 • ACR Convergence 2023
High-intensity Resistance Training Improves Quality of Life, Muscle Endurance and Strength in Patients with Myositis
Kasper Jensen¹, Per Aagaard², Charlotte Suetta³, Jakob Nielsen², Rune Bech⁴, Henrik Schrøder¹, Casper Simonsen¹, Jan Christensen¹ and Louise Pyndt Diederichsen⁵, ¹University Hospital of Copenhagen, Rigshospitalet, Copenhagen, Denmark, ²University of Southern Denmark, Odense, Denmark, ³Bispebjerg Hospital, Copenhagen, Denmark, ⁴Zealand University Hospital, Koege, Dragør, Denmark, ⁵University Hospital of Copenhagen, Rigshospitalet, Dragør, Denmark
Background/Purpose: Myositis is associated with muscle impairment, which impacts quality of life. The purpose of this study was to investigate the effects of high-intensity strength…
Abstract Number: 0526 • ACR Convergence 2023
Bimekizumab Improved Physical Function and Health-Related Quality of Life in Patients with Axial Spondyloarthritis: 52-Week Results from Two Phase 3 Studies
Maureen Dubreuil¹, Karl Gaffney², Jonathan Kay³, Victoria Navarro-Compán⁴, Christine de la Loge⁵, Alicia Ellis⁶, Carmen Fleurinck⁷, Ute Massow⁸, Vanessa Taieb⁹ and Atul Deodhar¹⁰, ¹Department of Rheumatology, Boston University School of Medicine, Milton, MA, ²Norfolk and Norwich University Hospital NHS Trust, Norfolk, United Kingdom, ³Division of Rheumatology, Department of Medicine, UMass Chan Medical School and UMass Memorial Medical Center, Worcester, MA, ⁴Department of Rheumatology, La Paz University Hospital, IdiPaz, Madrid, Spain, ⁵UCB Pharma, Brussels, Belgium, ⁶UCB Pharma, Raleigh, NC, ⁷UCB Pharma, Oosterzele, Belgium, ⁸UCB Pharma, Monheim am Rhein, Germany, ⁹UCB Pharma, Colombes, France, ¹⁰Division of Arthritis and Rheumatic Disease, Oregon Health & Science University, Portland, OR
Background/Purpose: Axial spondyloarthritis (axSpA) severely impairs physical function and health-related quality of life (HRQoL).1 Bimekizumab (BKZ), a monoclonal IgG1 antibody that selectively inhibits IL-17F in…
Abstract Number: 2587 • ACR Convergence 2023
Measuring Frailty in SLE: Agreement Among Methods
Patti Katz¹, Maria Dall'Era², Kamil Barbour³, Kurt Greenlund³, Cristina Lanata⁴, Caroline Gordon⁵, Lindsey Criswell⁶ and Jinoos Yazdany⁷, ¹University of California San Francisco, San Rafael, CA, ²University of California San Francisco, San Francisco, CA, ³Centers for Disease Control and Prevention, Atlanta, GA, ⁴National Human Genome Research Institute, Washington, DC, ⁵Institute of Inflammation and Ageing, University of Birmingham, Birmingham, United Kingdom, ⁶NIH/NHGRI, Bethesda, MD, ⁷University of California, General Department of Medicine, Division of Rheumatology, San Francisco, CA
Background/Purpose: Frailty, conceptualized as an accumulation of deficits across multiple physiological systems, was first examined in SLE in 2017 using the Fried Frailty Phenotype criteria…
Abstract Number: 0620 • ACR Convergence 2023
Physical and Mental Health in Early Systemic Sclerosis: Baseline Results for Patient-Reported Outcomes Measurement Information System-29 from the Collaborative National Quality and Efficacy Registry
Isha Lamba¹, Ashima Makol², Dinesh Khanna³, John VanBuren⁴, Angela Child⁴, Jessica Alvey⁴, Shervin Assassi⁵, Elana Bernstein⁶, Flavia Castelino⁷, Lorinda Chung⁸, Luke Evnin⁹, Tracy Frech¹⁰, Faye Hant¹¹, Laura Hummers¹², Kimberly Lakin¹³, Dorota Lebiedz-Odrobina¹⁴, Yiming Luo¹⁵, Jerry Molitor¹⁶, Duncan Moore¹⁷, Carrie Richardson¹⁸, Nora Sandorfi¹⁹, Ami Shah²⁰, Ankoor Shah²¹, Victoria Shanmugam²², Brian Skaug²³, Virginia Steen²⁴, Elizabeth Volkmann²⁵ and Jessica Gordon¹³, ¹New York Presbyterian Hospital/Weill Cornell Medical Centre, New York, NY, ²Mayo Clinic, Rochester, MN, Rochester, MN, ³University of Michigan, Ann Arbor, MI, ⁴University of Utah, Salt Lake City, UT, ⁵University of Texas McGovern Medical School at Houston, Houston, TX, ⁶Columbia University, New York, NY, ⁷Massachusetts General Hospital, Boston, MA, ⁸Department of Medicine, Division of Immunology and Rheumatology, Stanford University School of Medicine, Woodside, CA, ⁹Scleroderma Research Foundation, Brisbane, CA, ¹⁰Vanderbilt University Medical Center, Nashville, TN, ¹¹Medical University of South Carolina, Charleston, SC, ¹²Johns Hopkins University, Baltimore, MD, ¹³Hospital for Special Surgery, New York, NY, ¹⁴University of Utah, Cottonwood Heights, UT, ¹⁵Division of Rheumatology, Department of Medicine, Columbia University Irving Medical Center, New York, NY, ¹⁶University of Minnesota, Minneapolis, MN, ¹⁷Northwestern Memorial Hospital, Chicago, IL, ¹⁸Northwestern University, Riverside, IL, ¹⁹University of Pennsylvania, Philadelphia, PA, ²⁰Department of Medicine, Division of Rheumatology, Johns Hopkins University School of Medicine, Ellicott City, MD, ²¹Duke University, Durham, NC, ²²Victoria Shanmugam, MD, Great Falls, VA, ²³Division of Rheumatology, University of Texas McGovern Medical School, Houston, TX, ²⁴Georgetown University School of Medicine, Washington, DC, ²⁵University of California Los Angeles, Los Angeles, CA
Background/Purpose: Patient-Reported Outcomes Measurement Information System-29 version 2.0 (PROMIS-29v2) is a patient-centered questionnaire used to assess health-related quality of life (HRQoL). PROMIS-29v2 has shown validity…
Abstract Number: 0629 • ACR Convergence 2023
Negative Affect, Anxiety and Fatigue Moderate the Association Between Pain Intensity and Physical Function in People with Systemic Sclerosis
Daniel Whibley¹, Yen Chen¹, Anna Kratz¹, Dinesh Khanna¹ and Susan Murphy², ¹University of Michigan, Ann Arbor, MI, ²University of Michigan, Plymouth, MI
Background/Purpose: Pain is a common symptom of systemic sclerosis (SSc), affecting over 80% of those living with the condition, with over a third experiencing pain…
Abstract Number: 0990 • ACR Convergence 2023
Association of Treatment and Disease Activity with Antibiotic Use and Hospitalized Infection Among People Living with Rheumatoid Arthritis: Baseline Data from a Longitudinal Study in the ArthritisPower Registry
Kelly Gavigan¹, Esteban Rivera², Odette Kolenky³, Cassie Clinton⁴, Emily Holladay⁴, David Curtis⁵, Laura Stradford⁶, Jeffrey Curtis⁴, W. Benjamin Nowell⁶, Christian Curtis⁷ and Michael George⁸, ¹Global Healthy Living Foundation, Upper Nyack, NY, ²Global Healthy Living Foundation, Long Island City, NY, ³Hospital of the University of Pennsylvania, Philadelphia, PA, ⁴University of Alabama at Birmingham, Birmingham, AL, ⁵Global Healthy Living Foundation, San Francisco, CA, ⁶Global Healthy Living Foundation, Nyack, NY, ⁷Illumination Health, Birmingham, AL, ⁸University of Pennsylvania, Philadelphia, PA
Background/Purpose: Infections are a major contributor to morbidity and mortality in patients (pts) with rheumatoid arthritis (RA). Little is known about the risk of non-serious…
Abstract Number: 1277 • ACR Convergence 2023
Relationship Between Quality of Life and the Region of the Affected Joints in Japanese Patients with Rheumatoid Arthritis: A Cross-sectional Study
Kenichiro Tokunaga¹, Takahiro Nishino², Hideto Oshikawa¹, Toshihiro Matsui³ and Shigeto Tohma⁴, ¹Japanese Red Cross Kumamoto Hospital, Kumamoto, Japan, ²National Hospital Organization Sagamihara National Hospital, Kanagawa, Japan, ³NHO Sagamihara National Hospital, Kanagawa, Japan, ⁴NHO Tokyo National Hospital, Dallas, TX
Background/Purpose: This clinical study aimed to investigate the relationship between affected joints and the quality of life (QOL) in patients with rheumatoid arthritis (RA) in…
Abstract Number: 1278 • ACR Convergence 2023
Nature and Severity of Activity Limitations According to the Health Assessment Questionnaire Disability Index in Patients with Rheumatoid Arthritis and Functional Disability
Manja van Wissen¹, Maaike gademan¹, Cornelia van den Ende², Max Teuwen¹, Wilfred Peter¹, Dirkjan van Schaardenburg³, Alfons den Broeder², Thea Vliet Vlieland⁴ and Salima van Weely¹, ¹Leiden University Medical Center, Leiden, Netherlands, ²Sint Maartenskliniek, Nijmegen, Netherlands, ³Reade, Amsterdam, Netherlands, ⁴Leids University Medical Center, Leiden, Netherlands
Background/Purpose: Not withstanding modern treatment, some Rheumatoid Arthritis (RA) patients have severe disability due to persistently high disease activity, joint destruction/deformities and/or comorbidities. Insight into…
Abstract Number: 1279 • ACR Convergence 2023
What Is the Nature of Functional Problems in People with Rheumatoid Arthritis and Severe Disability; An Analysis Using the International Classification of Functioning, Disability and Health as a Reference
Max Teuwen¹, Salima van Weely¹, Thea Vliet Vlieland², Thom Douw³, Manja van Wissen¹, Alfons den Broeder⁴, Dirkjan van Schaardenburg⁵, Cornelia van den Ende⁴ and Maaike gademan¹, ¹Leiden University Medical Center, Leiden, Netherlands, ²Leids University Medical Center, Leiden, Netherlands, ³Leiden University of Applied Sciences, Leiden, Netherlands, ⁴Sint Maartenskliniek, Nijmegen, Netherlands, ⁵Reade, Amsterdam, Netherlands
Background/Purpose: There is a lack of knowledge about the limitations in activities and participation experienced by a subgroup of people with rheumatoid arthritis (RA) and…
Abstract Number: 1293 • ACR Convergence 2023
Single Camera Hand Motion Capturing as a Digital Biomarker for Disease Activity in Rheumatoid Arthritis Using Computer Vision: The Proof-of-Concept MeFisto Study
Vincenzo Venerito¹, Tobias Maningold², Deborah Markham³, Marc Blanchard⁴, Florenzo Iannone¹ and Thomas Hügle⁵, ¹Rheumatology Unit, Department of Precision and Regenerative Medicine and Ionian Area, University of Bari "Aldo Moro", Bari, Italy, ²Department of Rheumatology, University Hospital Bern (Inselspital), University Bern, Bern, Switzerland, ³on behalf of Department Rheumatology, University Hospital Lausanne, Lausanne, Switzerland, ⁴Dept. of Rheumatology, University Hospital Lausanne (CHUV) and University Lausanne, Lausanne, Switzerland, ⁵Dept. of Rheumatology, University Hospital Lausanne (CHUV) and University of Lausanne, Lausanne, Switzerland
Background/Purpose: Computer vision technology offerspromising possibilities for remotely assessing disease activity in rheumatoid arthritis (RA) patients, enabling telemedicine and improving access to care. The objective…
Abstract Number: 0207 • ACR Convergence 2022
Novel Digital Technologies for the Assessment of Objective Measures and PROs in Patients with Rheumatoid Arthritis: A Pilot Study Using Smart Devices and a Bespoke Mobile App
Valentin Hamy¹, Christopher Llop², Christopher W Yee², Luis Garcia-Gancedo³, Aoife Maxwell⁴, Wen-Hung Chen⁵, Ryan Tomlinson³, Priyanka Bobbili², Julien Bendelac², Jessica Landry², Maral DerSarkissian⁶, Mihran Yenikomshian², Elinor A Mody⁷, Mei Sheng Duh² and Rachel Williams³, ¹GlaxoSmithKline, London, United Kingdom, ²Analysis Group Inc, Boston, MA, ³GlaxoSmithKline, Philadephia, ⁴GlaxoSmithKline, Stevenage, United Kingdom, ⁵GlaxoSmithKline, Value Evidence and Outcomes, Philadephia, ⁶Analysis Group Inc, Los Angeles, CA, ⁷Reliant Medical Group, Worcester, MA
Background/Purpose: RA symptoms are typically only assessed intermittently in clinical practice and clinical trials. Digital technologies (wearables, smartphones) can facilitate continuous remote monitoring of patients'…
Abstract Number: 2118 • ACR Convergence 2022
Achieving Increasingly Stringent Clinical Disease Control Criteria Is Associated with Greater Improvements in Patient-Centric Measures of Physical Function and Pain in Patients with Active PsA: 16-Week Results from Two Phase 3 Randomized, Placebo-Controlled Studies
Jessica Walsh¹, Laura Coates², Philip J Mease³, Joseph Merola⁴, Peter Nash⁵, Alexis Ogdie⁶, William Tillett⁷, Paolo Gisondi⁸, Barbara Ink⁹, Deepak Assudani⁹, Rajan Bajracharya⁹, Jérémy Lambert¹⁰, Vanessa Taieb¹¹, Damon Willems¹² and Lars Erik¹³, ¹University of Utah, Salt Lake City, UT, ²Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK, Oxford, England, United Kingdom, ³Swedish Medical Center/Providence St. Joseph Health, Seattle, WA, ⁴Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ⁵School of Medicine, Griffith University, Sunshine Coast, Australia, ⁶Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ⁷Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, ⁸Dermatology and Venereology, Department of Medicine, Università di Verona, Verona, Italy, Verona, ⁹UCB Pharma, Slough, United Kingdom, ¹⁰UCB Pharma, Colombes, France, Irigny, France, ¹¹UCB Pharma, Colombes, France, ¹²UCB Pharma, Brussels, Belgium, ¹³Bispebjerg-Frederiksberg Hospital, Vedbæk, Denmark
Background/Purpose: Examine the association between achieving increasingly stringent clinical disease control criteria and patient-centric measures of physical function and pain in patients with PsA, using…
Abstract Number: 0410 • ACR Convergence 2022
Achieving Increasingly Stringent Clinical Response Criteria & Lower Levels of Disease Activity Is Associated with Greater Improvements in Physical Function & HRQoL in Patients with Active Axial Spondyloarthritis: 16-Week Results from Two Phase 3 Randomized, Placebo-Controlled Studies
Marina Magrey¹, Atul Deodhar², Philip J Mease³, Victoria Navarro-Compán⁴, Sofia Ramiro⁵, Martin Rudwaleit⁶, Christine de la Loge⁷, Carmen Fleurinck⁸, Vanessa Taieb⁹, Michael Frank Mørup¹⁰, Marga Oortgiesen¹¹ and Jonathan Kay¹², ¹Case Western Reserve University, University Hospitals, Richfield, OH, ²Oregon Health & Science University, Portland, OR, USA, Portland, OR, ³Swedish Medical Center/Providence St. Joseph Health, Seattle, WA, ⁴Department of Rheumatology, La Paz University Hospital, IdiPaz, Madrid, Spain, ⁵Leiden University Medical Center, Leiden, Netherlands, ⁶University of Bielefeld, Klinikum Bielefeld, Bielefeld; Germany Klinikum Bielefeld and Charité Berlin, Germany, and Gent University, Gent, Belgium, ⁷UCB Pharma, Brussels, Belgium, ⁸UCB Pharma, Brussels, Belgium, Oosterzele, Belgium, ⁹UCB Pharma, Colombes, France, ¹⁰UCB Pharma, Copenhagen, Denmark, ¹¹UCB Pharma, Raleigh, NC, ¹²Division of Rheumatology, Department of Medicine, UMass Chan Medical School and UMass Memorial Medical Center, Worcester, MA
Background/Purpose: Examine the association between achieving increasingly stringent clinical response criteria and lower levels of disease activity, and improvements in physical function and health-related quality…
Abstract Number: 2239 • ACR Convergence 2022
Effect of Treatment with IVIG (octagam10%) on Skin Symptoms and Quality of Life in Subjects with Dermatomyositis. Results of a Large, Randomized, Placebo-controlled International Phase III Trial
Rohit Aggarwal¹, Christina Charles-Schoeman², joachim Schessl³, Victoria Werth⁴, Zsuzsanna Bata-Csorgo⁵, Mazen Dimachkie⁶, Zoltan Griger⁷, Sergey Moiseev⁸, Chester Oddis⁹, Elena Schiopu¹⁰, Jiří Vencovský¹¹, Irene Beckmann¹², Elisabeth Clodi¹³, Todd Levine¹⁴ and and the ProDERM investigators¹⁵, ¹Division of Rheumatology and Clinical Immunology, Department of Medicine, University of Pittsburgh, Pittsburgh, PA, ²Division of Rheumatology, University of California, Los Angeles, Santa Monica, CA, ³Friedrich-Baur-Institut/Medical University Munich, Mainkofen, Germany, ⁴Philadelphia VAMC, Philadelphia, PA, USA and Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, ⁵University of Szeged, Faculty of Medicine, Szeged, Hungary, ⁶University of Kansas Medical Center, Kansas City, KS, ⁷University of Debrecen, Debrecen, Hungary, ⁸First Moscow State Medical University, Moscow, Russia, ⁹University of Pittsburgh, Pittsburgh, PA, ¹⁰Michigan Medicine Rheumatology Clinic – Taubman Center, Ann Arbor, MI, ¹¹Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, ¹²Octapharma PharmazeutikaProduktionsGesmbH, Vienna, Austria, ¹³Octapharma Pharmazeutika ProduktionsgesmbH, Vienna, Austria, ¹⁴Phoenix Neurological Associates, Ltd., Phoenix, AZ, ¹⁵Institutions in Europe and North America, Vienna, Austria
Background/Purpose: Dermatomyositis (DM) is a rare chronic systemic autoimmune disease with characteristic skin rashes and progressive proximal muscle weakness. The efficacy of IVIg treatment in…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].